Corneal haze is a potential complication of refractive surgery, particularly after PRK, but also seen after LASIK, SMILE, and other corneal procedures. It results from TGF-ß-mediated myofibroblast activation, abnormal collagen deposition, and reduced corneal transparency. While most cases are mild and self-resolving, 0.5–3% of patients develop significant haze, causing reduced visual acuity, myopic regression, and irregular astigmatism. Advancements in laser technology, such as flying spot and wavefront-guided ablation, have reduced haze incidence by promoting smoother corneal surfaces and better healing. Mitomycin C (MMC) is highly effective in both preventing and treating haze. Preoperative identification of risk factors, including dry eye, ultraviolet exposure, and nutritional deficiencies, is crucial for minimizing haze. Haze is graded from 0 (no haze) to 4 (total obscuration of the anterior chamber). Two types exist: (1) typical transitory haze, appearing 1–3 months postoperatively and resolving within a year, and (2) late haze, emerging 2–5 months postoperatively and potentially persisting for up to 3 years, with greater visual impact. Prevention is the primary strategy, with MMC playing a key role. Proper preoperative planning and addressing risk factors are essential for optimizing outcomes and selecting the most suitable refractive procedure.